Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Salutsantjoan     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon


My photo
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com




Saturday, April 21, 2012

Nuevos anticoagulantes

ESC issues position paper on new anticoagulants
Chieti, Italy - In a "position paper" on the new oral anticoagulants, a group of experts from the European Society of Cardiology Working Group on Thrombosis are enthusiastic about the new agents in AF, but not so impressed with their use in ACS (1)
To heartwire, lead author of the position paper, Dr Raffaele De Caterina (G d'Annunzio University, Chieti, Italy), commented: "We are comparing data from different trials, so these are indirect comparisons, and therefore it is difficult to reach any firm conclusions. But if I had to rank the results of the three major trials in AF, I would put ARISTOTLE with apixaban at the top, with RE-LY (dabigatran) second and ROCKET (rivaroxaban) third."
(1) De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012; 59:1413-25